+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Major Depressive Disorder Drug"

United States SAGE-217 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States SAGE-217 Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • United States
From
REXULTI Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

REXULTI Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • July 2023
  • 30 Pages
  • Global
From
From
Major Depressive Disorder - Epidemiology Forecast - 2032 - Product Thumbnail Image

Major Depressive Disorder - Epidemiology Forecast - 2032

  • Report
  • June 2022
  • 148 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Depression Treatment Drugs Companies in China - Product Thumbnail Image

Depression Treatment Drugs Companies in China

  • Report
  • March 2025
  • 55 Pages
  • China
From
Fetzima (levomilnacipran; Allergan) Drug Overview 2019 - Product Thumbnail Image

Fetzima (levomilnacipran; Allergan) Drug Overview 2019

  • Report
  • March 2019
  • 17 Pages
  • Global
Loading Indicator

The Major Depressive Disorder Drug market is a subset of the Mental Disorders Drugs market. It is composed of pharmaceuticals used to treat major depressive disorder, a mental health disorder characterized by persistent feelings of sadness, loss of interest, and fatigue. These drugs are typically prescribed by psychiatrists and other mental health professionals. Commonly prescribed drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). The Major Depressive Disorder Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and Novartis. Show Less Read more